AbbVie Inc.
AbbVie Appoints Robert A. Michael as New CEO
Summary
AbbVie Inc. announced on February 20, 2024, that its Board of Directors has selected Robert A. Michael to succeed Richard A. Gonzalez as Chief Executive Officer (CEO) effective July 1, 2024. Mr. Gonzalez, who has served as CEO since the company's formation in 2013, will retire from the CEO role and become Executive Chairman of the Board. Mr. Michael, currently AbbVie's President and Chief Operating Officer, brings over 30 years of experience in leadership roles across multiple businesses within the company. The transition marks a planned succession to ensure a seamless leadership change and continued growth for AbbVie.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement